Good to hear from you again..was beginning to wonder where you had got to! Yes, in full agreement with your comments having watched it with interest. Not long to wait now. Have been with Summit since May 2012 and I think we have all shared the promise that this company undoubtedly has and the frustrating times that we all know about. As you say 'Good luck everyone' and yes I have good feeling about this one now!
RE: PPMD's 2015 Connect Conference ..
Hi Chris - many thanks for posting that PPMD link ( courtesy algernon2) Thought , Mike Boss presentation style & delivery excellent , quite refreshing honest comments re –previous dietary issues with drug absorption etc ! This time round Phase1b patient management programme more strictly controlled , so best possible chance of positive data outcomes . Results presented by end September - not that long to wait -- fingers crossed ! Summit still offers two good chances for a very handsome investment return with both SMTC1100 & SMT19969 still very much in play ! Good luck everyone !
PPMD's 2015 Connect Conference Link
Thanks to algernon2 from the other Board re: Summits presentation at the conference (hopefully DMD results next month): --------- hTTps://www.youtube.com/watch?v=_4NGpzIiKmU---------- Summit Therapeutics (C1100) [PPMD's 2015 Connect Conference]
Average price target $30 with...
... current data and analysis. This obviously all goes north on +ve clinical stage results....as expected over the coming months in both key programmes. GLA http://www.watchlistnews.com/analysts-set-30-00-target-price-for-summit-therapeutic-nasdaqsmmt/198855/ "Analysts have set a 1-year consensus target price of $30.00 for the company and are predicting that the company will post ($0.06) EPS for the current quarter, according to Zacks. Zacks has also assigned Summit Therapeutic an industry rank of 98 out of 265 based on the ratings given to its competitors. " "Several research firms have recently commented on SMMT. Oppenheimer reaffirmed an “outperform” rating and issued a $28.00 price objective on shares of Summit Therapeutic in a research note on Friday, July 10th. Needham & Company LLC reissued a “buy” rating and set a $22.00 price target on shares of Summit Therapeutic in a research report on Friday, June 12th. Finally, JMP Securities began coverage on Summit Therapeutic in a report on Thursday, April 2nd. They set an “outperform” rating and a $32.00 price objective on the stock."
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.